Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma
Status:
Recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Currently, combined chemotherapy (CT) and radiation (RT) is recognized as the standard
treatment for high-risk early-stage NKTCL. However, treatment failure occured in nearly 30%
of patients receiving CRT and systemic failure are the most common failure form. Chidamide is
a HADC inhibitor, which presents satisfactory efficacy in NKTCL especially in terms of
improving durable remission time. In our previous study, IMRT followed by GDP was
demonstrated effective in early-stage NKTCL. Therefore, we designed a prospective phase II
clinical trial of IMRT followed by GDP with or without chidamide in patients with high-risk
early-stage NKTCL.